Answers are grounded in this paper and cite their sources.
This research demonstrates that ionizing radiation promotes glioblastoma recurrence through senescence and suggests senolytic therapy for treatment.
Glioblastomas (GBM) are treated with high doses of ionizing radiation (IR), yet these tumors inevitably recur, and the recurrent tumors are highly therapy resistant, the underlying mechanisms of which are not completely understood. During GBM therapy, both the tumor and the normal brain tissue surrounding the tumor are treated with up to 60 Gy of IR. We have shown previously that IR-induced senescence of astrocytes in the brain leads to the secretion of senescence-associated secretory phenotype (SASP) factors that promote the growth and invasiveness of tumor cells in mouse models of GBM. Following up on this study, we irradiated a panel of GBM cell lines and PDX cultures and found that a significant fraction of these cells senesced rapidly in a p21-dependent manner. Senescent glioma cells upregulated SASP genes in a NF-kB-dependent manner, prominently, the interleukin IL6, which is an activator of the JAK-STAT pathway. Conditioned media from senescent GBM cells activated the JAK-STAT pathway in non-senescent GBM cells and promoted tumor cell proliferation and radiation resistance. Bioinformatic analyses of the transcriptomic profiles of irradiated GBM cells and the TCGA database revealed that the inhibitor of apoptosis protein cIAP2 is a critical survival factor for senescent glioma cells. We find that targeting cIAP2 using SMAC mimetics triggers apoptosis of senescent GBM cells with minimal toxicity towards normal brain cells like astrocytes. Using both PDX and immunocompetent mouse models of GBM, we show that the SMAC mimetic birinapant can eliminate senescent GBM cells and delay recurrence. Our findings illustrate how senescence of both stromal and tumor cells promote GBM recurrence via different mechanisms and underscore the potential utility of adjuvant senolytic therapy for blunting GBM recurrence. Ongoing studies are focused on combinatorial treatment with birinapant (to remove senescent GBM cells) and navitoclax (to remove senescent astrocytes) in order to prevent recurrence.
No takes yet. Share an insight, caveat, or question.
Mukherjee et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: